UNLABELLED: The baseline platelet count (BPC) in patients with acute ST elevation myocardial infarction (STEMI) may reflect the baseline anjiografic finding and may also predic long-term outcomes after primary percutaneous coronary intervention (PPCI). Available data for the value of BPC in patients with STEMI treated with PPCI are still questionable. Therefore, we sought to determine the prognostic value of BPC for baseline angiographic finding and the impact of BPC on clinical outcomes of patients treating with PPCI. Blood sample for BPC was obtained on admission in 140 consecutive patients undergoing PPCI. Patients were divided 2 groups that group-1 (104 patients): TIMI flow-grade 0 and group-2 (36 patients): TIMI flow-grade 1-3. Follow-up was performed at 1-9 months. Baseline demographics were comparable, but, BPC was significantly higher in group-1 comparing 2 (293.7±59.8x10(9)/L vs. 237.7±50.9x10(9)/L, p<0.0001), pre-procedural lesion length longer in group-1 comparing 2 (13.6±3.6 mm vs. 11.4±3.9 mm, p:0.003). Distal embolization (19.0% vs. 0.0%, p:0.001), slow-flow (15.2% vs. 2.9%, p:0.033) were more common in group-1 and mean maximum troponin-I level (9.1±4.2 μg/L vs. 5.1±3.9 μg/L, p<0.0001) and mean maximum creatinin kinase (2077.6±1378.4 U/L vs. 1163.4±869.7 U/L, p:<0.0001) were higher in group-1. In-hospital and 30-days major cardiac adverse events (MACEs) (16.5% vs. 5.7%), p:0.14) were similarly in both groups, but, at 6-months target vessel revascularization (13.9% vs. 0.0%, p:0.017) and MACEs significantly higher in the group-1 (24.1% vs. 2.9%, p:0.013). CONCLUSION: A higher BPC without any antithrombotic agent is a strongly predictor of total occlusion of IRA in STEMI treated with PPCI. And a higher BPC associated with poor clinical outcomes at 9-months. Apart from prognostic value, measuring of a BPC on admission may also provide further practical and therapeutic profits.
UNLABELLED: The baseline platelet count (BPC) in patients with acute ST elevation myocardial infarction (STEMI) may reflect the baseline anjiografic finding and may also predic long-term outcomes after primary percutaneous coronary intervention (PPCI). Available data for the value of BPC in patients with STEMI treated with PPCI are still questionable. Therefore, we sought to determine the prognostic value of BPC for baseline angiographic finding and the impact of BPC on clinical outcomes of patients treating with PPCI. Blood sample for BPC was obtained on admission in 140 consecutive patients undergoing PPCI. Patients were divided 2 groups that group-1 (104 patients): TIMI flow-grade 0 and group-2 (36 patients): TIMI flow-grade 1-3. Follow-up was performed at 1-9 months. Baseline demographics were comparable, but, BPC was significantly higher in group-1 comparing 2 (293.7±59.8x10(9)/L vs. 237.7±50.9x10(9)/L, p<0.0001), pre-procedural lesion length longer in group-1 comparing 2 (13.6±3.6 mm vs. 11.4±3.9 mm, p:0.003). Distal embolization (19.0% vs. 0.0%, p:0.001), slow-flow (15.2% vs. 2.9%, p:0.033) were more common in group-1 and mean maximum troponin-I level (9.1±4.2 μg/L vs. 5.1±3.9 μg/L, p<0.0001) and mean maximum creatinin kinase (2077.6±1378.4 U/L vs. 1163.4±869.7 U/L, p:<0.0001) were higher in group-1. In-hospital and 30-days major cardiac adverse events (MACEs) (16.5% vs. 5.7%), p:0.14) were similarly in both groups, but, at 6-months target vessel revascularization (13.9% vs. 0.0%, p:0.017) and MACEs significantly higher in the group-1 (24.1% vs. 2.9%, p:0.013). CONCLUSION: A higher BPC without any antithrombotic agent is a strongly predictor of total occlusion of IRA in STEMI treated with PPCI. And a higher BPC associated with poor clinical outcomes at 9-months. Apart from prognostic value, measuring of a BPC on admission may also provide further practical and therapeutic profits.
Authors: Hung Q Ly; Ajay J Kirtane; Sabina A Murphy; Jacki Buros; Christopher P Cannon; Eugene Braunwald; C Michael Gibson Journal: Am J Cardiol Date: 2006-04-27 Impact factor: 2.778
Authors: C Michael Gibson; Hung Q Ly; Sabina A Murphy; Lauren N Ciaglo; Matthew C Southard; Erica B Stein; Jacqueline L Buros; Marc S Sabatine; Christopher P Cannon Journal: Am J Cardiol Date: 2006-08-02 Impact factor: 2.778
Authors: Minang P Turakhia; Sabina A Murphy; Tina L Pinto; Elliott M Antman; Robert P Giugliano; Christopher P Cannon; Eugene Braunwald; C Michael Gibson Journal: Am J Cardiol Date: 2004-12-01 Impact factor: 2.778
Authors: Zenon Huczek; Janusz Kochman; Krzysztof J Filipiak; Grzegorz J Horszczaruk; Marcin Grabowski; Radoslaw Piatkowski; Joanna Wilczynska; Andrzej Zielinski; Bernhard Meier; Grzegorz Opolski Journal: J Am Coll Cardiol Date: 2005-07-19 Impact factor: 24.094
Authors: P Pabón Osuna; F Nieto Ballesteros; J L Moríñigo Muñoz; P L Sánchez Fernández; A Arribas Jiménez; M Diego Domínguez; C Martín Luengo Journal: Rev Esp Cardiol Date: 1998-10 Impact factor: 4.753
Authors: Amir Halkin; Gregg W Stone; Cindy L Grines; David A Cox; Barry D Rutherford; Paolo Esente; Carol M Meils; Per Albertsson; Anthony Farah; James E Tcheng; Alexandra J Lansky; Roxana Mehran Journal: J Am Coll Cardiol Date: 2006-02-10 Impact factor: 24.094
Authors: Olga Sazonova; Yuqi Zhao; Sylvia Nürnberg; Clint Miller; Milos Pjanic; Victor G Castano; Juyong B Kim; Elias L Salfati; Anshul B Kundaje; Gill Bejerano; Themistocles Assimes; Xia Yang; Thomas Quertermous Journal: PLoS Genet Date: 2015-05-28 Impact factor: 5.917